


PHARMACEUTICAL 2018

## Checkpoint Therapeutics Inc. Rank 292 of 349









PHARMACEUTICAL 2018



## Checkpoint Therapeutics Inc. Rank 292 of 349

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 330% points.

The company's Economic Capital Ratio, given in the ranking table, is -544%, being 266% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	21,413
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,372
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	98
Property and Equipment	0
Research and Development	19,081
Revenues	1,725
Selling, General and Administrative Expense	5,419

Output Variable	Value in 1000 USD
Assets	21,413
Liabilities	6,372
Expenses	24,500
Stockholders Equity	15,041
Net Income	-22,677
Comprehensive Net Income	-22,677
Economic Capital Ratio	-544%

